Rocaltrol



Indications and Reactions:

Role Indications Reactions
Primary
Drug Use For Unknown Indication 21.5%
Osteoporosis 16.6%
Product Used For Unknown Indication 15.6%
Hypoparathyroidism 7.0%
Renal Transplant 6.3%
Hypocalcaemia 6.0%
Renal Failure Chronic 4.6%
Hyperparathyroidism Secondary 3.6%
Hypertension 3.3%
Hypothyroidism 2.6%
Hepatitis C 1.7%
Hyperparathyroidism 1.7%
Hypoparathyroidism Secondary 1.7%
Femur Fracture 1.3%
Parkinson's Disease 1.3%
Prostate Cancer Metastatic 1.3%
Calcium Deficiency 1.0%
Calcium Metabolism Disorder 1.0%
Chronic Hepatitis C 1.0%
Gastritis 1.0%
Hypercalcaemia 19.0%
Anaphylactic Shock 7.1%
Death 7.1%
Transient Ischaemic Attack 6.0%
Vomiting 6.0%
Decreased Appetite 4.8%
Renal Failure Acute 4.8%
Renal Impairment 4.8%
Therapeutic Product Contamination 4.8%
White Blood Cell Count Decreased 4.8%
Blood Calcium Decreased 3.6%
Cerebrovascular Accident 3.6%
Platelet Count Decreased 3.6%
Renal Failure 3.6%
Venous Thrombosis 3.6%
Vertigo 3.6%
Anaphylactic Reaction 2.4%
Drug Effect Decreased 2.4%
Erythema Multiforme 2.4%
Hepatic Function Abnormal 2.4%
Secondary
Drug Use For Unknown Indication 22.7%
Hypoparathyroidism 14.5%
Hypothyroidism 14.1%
Hypertension 7.9%
Renal Transplant 4.9%
Hypocalcaemia 4.6%
Product Used For Unknown Indication 3.3%
Rheumatoid Arthritis 3.3%
Coronary Artery Disease 3.0%
Osteoporosis 3.0%
Diabetes Mellitus 2.6%
Hyperlipidaemia 2.3%
Hyperparathyroidism 2.3%
Hyperthyroidism 2.3%
Cancer Pain 2.0%
Constipation 1.6%
Gastritis 1.6%
Attention Deficit/hyperactivity Disorder 1.3%
Benign Prostatic Hyperplasia 1.3%
Hyperparathyroidism Secondary 1.3%
Lenticular Opacities 10.1%
Post Procedural Complication 10.1%
Tinnitus 10.1%
Death 8.7%
Therapeutic Product Contamination 8.7%
Toxic Skin Eruption 5.8%
Angina Pectoris 4.3%
Hypercalcaemia 4.3%
Lung Disorder 4.3%
Medication Residue Present 4.3%
Renal Failure 4.3%
Renal Failure Acute 4.3%
Vomiting 4.3%
Hepatic Function Abnormal 2.9%
Pancreatitis 2.9%
Rash Morbilliform 2.9%
Renal Tubular Disorder 2.9%
Anaemia 1.4%
Coma 1.4%
Confusional State 1.4%
Concomitant
Product Used For Unknown Indication 30.0%
Drug Use For Unknown Indication 20.5%
Hypertension 6.8%
Rheumatoid Arthritis 6.3%
Osteoporosis 5.8%
Hyperphosphataemia 4.0%
Nuclear Magnetic Resonance Imaging 3.4%
Renal Failure Chronic 3.0%
Prophylaxis 2.6%
Pain 2.3%
Hyperparathyroidism Secondary 2.0%
Renal Transplant 1.9%
Diabetes Mellitus 1.6%
Prophylaxis Against Transplant Rejection 1.6%
Peritoneal Dialysis 1.6%
Constipation 1.5%
Insomnia 1.5%
Nephrogenic Anaemia 1.3%
Gastritis 1.3%
Behcet's Syndrome 1.1%
Vomiting 14.5%
Muscular Weakness 11.9%
Pyrexia 7.1%
Weight Decreased 5.4%
Pneumonia 5.2%
Urinary Tract Infection 5.2%
Renal Impairment 4.8%
Therapeutic Response Decreased 4.8%
Anaemia 4.3%
Cardiac Arrest 3.9%
Nephrogenic Systemic Fibrosis 3.9%
Wheezing 3.7%
Death 3.5%
Renal Failure Acute 3.5%
Renal Failure 3.2%
Thrombocytopenia 3.2%
Aplasia Pure Red Cell 3.0%
International Normalised Ratio Increased 3.0%
Rhabdomyolysis 3.0%
Sepsis 3.0%
Interacting
Chronic Myeloid Leukaemia 100.0%
Tremor 100.0%